Paris, August 28, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces that it has been named by Fierce Biotech as one of 2023’s ‘Fierce 15’ biotechnology companies, designating it as one of the most innovative and promising biotechnology companies in the industry.

Stéphane Boissel, President and Chief Executive Officer of SparingVision, said: “We are honored to be recognized among the prestigious Fierce 15 as a leading innovator in the biotech sector. This achievement underscores our commitment to tackling the urgent medical need of patients affected by blinding retinal diseases, and the strides we have made in developing a diverse portfolio of cutting-edge, genomic medicine products for ocular diseases. We eagerly anticipate the milestones ahead, particularly the progression of our ongoing first-in-human Phase I/II trial for SPVN06, PRODYGY in retinitis pigmentosa.”

 Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare said: “For the past 21 years, we have assessed hundreds of early-stage companies for inclusion in the ‘Fierce 15’ special report. To curate this list, we consider a diverse range of factors, including the robustness of their technology, partnerships, venture support and their competitive positioning within the market. Our special report celebrates innovation and creativity in the face of intense competition.”

This year’s full list of winners can be viewed here.

NOTES TO EDITORS:

About SparingVision
SparingVision is a clinical-stage genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new gene-independent treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.

SparingVision is a spin-off from the Paris Vision Institute and is backed by high-quality international investors including 4BIO Capital, AdBio Partners, Bpifrance, Fondation Voir & Entendre, Intellia Therapeutics, Jeito Capital, RD Fund (US), UPMC Enterprises, and Ysios Capital. Visit www.sparingvision.com for more and follow us on LinkedIn and Twitter @SparingVision.

About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories.

Miriam Cortes

See Full Bio